BR112022025667A2 - Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a - Google Patents

Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a

Info

Publication number
BR112022025667A2
BR112022025667A2 BR112022025667A BR112022025667A BR112022025667A2 BR 112022025667 A2 BR112022025667 A2 BR 112022025667A2 BR 112022025667 A BR112022025667 A BR 112022025667A BR 112022025667 A BR112022025667 A BR 112022025667A BR 112022025667 A2 BR112022025667 A2 BR 112022025667A2
Authority
BR
Brazil
Prior art keywords
treatment
inflammatory bowel
bowel disease
induction
dosage regimen
Prior art date
Application number
BR112022025667A
Other languages
English (en)
Inventor
Lynn Baniecki Mary
Hassan-Zahraee Mina
Eugene Hung Kenneth
Li Gang
Xi Li
Ye Zhan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112022025667A2 publication Critical patent/BR112022025667A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MÉTODOS DE TRATAMENTO DA DOENÇA INFLAMATÓRIA INTESTINAL COM ANTICORPOS TL1A. A presente invenção refere-se a um método para tratar a doença inflamatória intestinal (DII) em um paciente, o método compreendendo a administração ao paciente de um anticorpo de ligante semelhante a anti-TNF 1A (TL1A) em um regime de dosagem de indução suficiente para melhorar os sinais e sintomas de DII por pelo menos 12 semanas após o início do tratamento com o anticorpo anti-TL1A, o referido regime de dosagem de indução compreendendo uma pluralidade de doses de indução individuais, em que o método compreende também a administração ao paciente de um regime de dosagem de manutenção subsequente após a conclusão do regime de dosagem de indução, o referido regime de dosagem de manutenção compreendendo uma pluralidade de doses de manutenção individuais separadas umas das outras por pelo menos 2 semanas.
BR112022025667A 2020-06-26 2021-06-23 Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a BR112022025667A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063044390P 2020-06-26 2020-06-26
PCT/IB2021/055546 WO2021260577A2 (en) 2020-06-26 2021-06-23 Methods of treating inflammatory bowel disease with tl1a antibodies

Publications (1)

Publication Number Publication Date
BR112022025667A2 true BR112022025667A2 (pt) 2023-03-07

Family

ID=76730925

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025667A BR112022025667A2 (pt) 2020-06-26 2021-06-23 Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a

Country Status (9)

Country Link
US (1) US20230235070A1 (pt)
EP (1) EP4171632A2 (pt)
JP (1) JP2022022994A (pt)
KR (1) KR20230025898A (pt)
CN (1) CN116322762A (pt)
BR (1) BR112022025667A2 (pt)
CA (1) CA3187966A1 (pt)
MX (1) MX2022016590A (pt)
WO (1) WO2021260577A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3784699A4 (en) 2018-04-25 2022-04-13 Prometheus Biosciences, Inc. OPTIMIZED ANTI-TL1A ANTIBODIES
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
AR128226A1 (es) * 2022-01-07 2024-04-10 Prometheus Biosciences Inc Métodos para tratar enfermedades inflamatorias con una combinación de inhibidores de tl1a e inhibidores de il23
WO2024026395A1 (en) 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease
WO2024173877A1 (en) * 2023-02-17 2024-08-22 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the liver
CN118497088B (zh) * 2024-07-18 2024-10-01 北京大学人民医院 变异链球菌及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US7314622B2 (en) 2005-04-15 2008-01-01 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
JP2016536002A (ja) * 2013-09-06 2016-11-24 セダーズ−シナイ メディカル センター 抗ｔｌ１ａ療法のためのシステム、デバイス、及び方法
SG10201810298VA (en) * 2013-11-13 2018-12-28 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
EP3458466B1 (en) * 2016-05-20 2024-08-07 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
MY191324A (en) * 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
EP3784699A4 (en) * 2018-04-25 2022-04-13 Prometheus Biosciences, Inc. OPTIMIZED ANTI-TL1A ANTIBODIES

Also Published As

Publication number Publication date
WO2021260577A2 (en) 2021-12-30
WO2021260577A3 (en) 2022-04-28
MX2022016590A (es) 2023-02-01
US20230235070A1 (en) 2023-07-27
EP4171632A2 (en) 2023-05-03
JP2022022994A (ja) 2022-02-07
CA3187966A1 (en) 2021-12-30
CN116322762A (zh) 2023-06-23
KR20230025898A (ko) 2023-02-23

Similar Documents

Publication Publication Date Title
BR112022025667A2 (pt) Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a
Dong et al. Astragalus polysaccharides alleviates LPS‐induced inflammation via the NF‐κB/MAPK signaling pathway
Askarpour et al. Effect of bariatric surgery on serum inflammatory factors of obese patients: a systematic review and meta-analysis
Li et al. The effects of apigenin on lipopolysaccharide-induced depressive-like behavior in mice
Prado et al. Effects of β‐hydroxy β‐methylbutyrate (HMB) supplementation on muscle mass, function, and other outcomes in patients with cancer: a systematic review
Masoumi et al. Effect of combined use of calcium and vitamin B6 on premenstrual syndrome symptoms: a randomized clinical trial
Coyle Symptom management and lifestyle modifications in multiple sclerosis
Ghiasloo et al. Surgical treatment of stage IV colorectal cancer with synchronous liver metastases: A systematic review and network meta-analysis
Bansal et al. A secondary bile acid from microbiota metabolism attenuates ileitis and bile acid reduction in subclinical necrotic enteritis in chickens
Moludi et al. The efficacy and safety of probiotics intervention in attenuating cardiac remodeling following myocardial infraction: literature review and study protocol for a randomized, double-blinded, placebo controlled trial
Xu et al. Brain-gut-liver axis: Chronic psychological stress promotes liver injury and fibrosis via gut in rats
Audet Beyond the neuro-immune interplay in depression: Could gut microbes be the missing link?
Ono et al. Analysis of the effects of polyunsaturated fatty acids on transporter expressions using a PCR array: induction of xCT/SLC7A11 in human placental BeWo cells
Yoon et al. Endoscopic and percutaneous biliary interventions after liver transplantation: nationwide data in Korea
Zhang et al. Gestational folic acid administration alleviated maternal postpartum emotional and cognitive dysfunction in mice
BR112021006223A2 (pt) regime de dosagem para antagonistas de inibidor da via de fator tecidual (tfpi)
Yajnik Developmental origins of non-communicable diseases
Kalil et al. The association between preoperative chemotherapy and the prevalence of hepatic steatosis in hepatectomy for metastatic colorectal cancer
Li et al. Molecular mechanism by which the Notch signaling pathway regulates autophagy in a rat model of pulmonary fibrosis in pigeon breeder’s lung
Laplaud et al. Recommendations for the management of multiple sclerosis relapses
Chen et al. Bifidobacterium lactis Probio-M8 ameliorated the symptoms of type 2 diabetes mellitus mice by changing ileum FXR-CYP7A1
Rubin et al. A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, AN ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATE TO SEVERE ACTIVE, ANTI-TNFα AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS
UA138387U (uk) Спосіб лікування синдрому хронічної втоми
CN117860767A (zh) 复合益生元在制备治疗慢传输型便秘药物中的应用
Wong et al. Efficacy of Formulated Vitamins for Post-Bariatric Surgery Patients

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PFIZER INC. (US)

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]